As global markets show signs of optimism with cooling inflation and strong earnings reports, major U.S. stock indexes have rebounded, particularly favoring value stocks over growth shares. In this environment, identifying undervalued stocks becomes crucial as they may offer potential opportunities for investors seeking to capitalize on market inefficiencies.
Name | Current Price | Fair Value (Est) | Discount (Est) |
Atlantic Union Bankshares (NYSE:AUB) | US$37.87 | US$75.61 | 49.9% |
Dongsung FineTec (KOSDAQ:A033500) | ₩18390.00 | ₩36679.19 | 49.9% |
Thai Coconut (SET:COCOCO) | THB10.80 | THB21.59 | 50% |
Gaming Realms (AIM:GMR) | £0.36 | £0.72 | 49.9% |
Sudarshan Chemical Industries (BSE:506655) | ₹1114.70 | ₹2219.89 | 49.8% |
Equity Bancshares (NYSE:EQBK) | US$43.13 | US$86.02 | 49.9% |
LifeMD (NasdaqGM:LFMD) | US$4.90 | US$9.77 | 49.8% |
Shinko Electric Industries (TSE:6967) | ¥5879.00 | ¥11701.39 | 49.8% |
Hd Hyundai MipoLtd (KOSE:A010620) | ₩129300.00 | ₩257307.05 | 49.7% |
Vista Group International (NZSE:VGL) | NZ$3.19 | NZ$6.18 | 48.4% |
Click here to see the full list of 875 stocks from our Undervalued Stocks Based On Cash Flows screener.
Let's uncover some gems from our specialized screener.
Overview: Revenio Group Oyj specializes in ophthalmological devices and software for diagnosing glaucoma, macular degeneration, and diabetic retinopathy across Finland, Europe, North America, and internationally with a market cap of €769.69 million.
Operations: The company's revenue is primarily generated from its Health Tech segment, which amounted to €102.49 million.
Estimated Discount To Fair Value: 36.5%
Revenio Group Oyj is trading at €28.94, significantly below its estimated fair value of €45.56, suggesting it may be undervalued based on discounted cash flow analysis. With earnings forecast to grow 18.8% annually—outpacing the Finnish market—and revenue expected to rise by 12.1% per year, the company shows strong growth potential despite recent stable net income figures and modest sales increases reported in Q3 2024 results (€23.9 million).
Overview: Surgical Science Sweden AB (publ) develops and markets virtual reality simulators for evidence-based medical training globally, with a market cap of SEK8.93 billion.
Operations: The company generates revenue from Industry/OEM at SEK419.66 million and Educational Products at SEK440.17 million.
Estimated Discount To Fair Value: 47.2%
Surgical Science Sweden, trading at SEK175, is significantly undervalued with a fair value estimate of SEK331.54 based on discounted cash flow analysis. The company's earnings are projected to grow 36.1% annually, surpassing the Swedish market's growth rate. Recent developments include a strengthened collaboration with Intuitive for its da Vinci 5 systems and an acquisition agreement with Intelligent Ultrasound Group plc, indicating strategic expansion efforts despite recent dips in quarterly net income and sales figures.
Overview: NagaCorp Ltd. is an investment holding company that manages and operates a hotel and casino complex in Cambodia, with a market cap of HK$13 billion.
Operations: The company's revenue primarily comes from casino operations, generating $545.61 million, complemented by hotel and entertainment operations contributing $23.22 million.
Estimated Discount To Fair Value: 17.3%
NagaCorp, trading at HK$2.94, is undervalued with a fair value estimate of HK$3.56 based on discounted cash flow analysis. Earnings are forecast to grow significantly at 42.5% annually, outpacing the Hong Kong market's growth rate of 11.2%. Despite lower profit margins compared to last year and large one-off items impacting results, revenue growth exceeds the market average. Recent board changes include Ms. Monica Lam's transition from company secretary to non-executive director.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include HLSE:REG1V OM:SUS and SEHK:3918.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。